TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times (ESCAPE) Trial
Brief Summary: The purpose of the study is to understand whether a new treatment of stroke - endovascular clot removal - can be added to the current standard of care to improve patient outcomes.

All patients will receive the best standard stroke treatment. This includes treating patients with the clot dissolving drug tPA (tissue plasminogen activator). However, t-PA does not work in some patients and others are not eligible to receive t-PA because they present too late for treatment (they woke up with their stroke symptoms or their stroke was not witnessed).

During endovascular revascularization the blockage in the artery is removed with the use of devices called stentreivers and or by giving clot dissolving drug at the site of the blockage in the artery to restore blood flow. Stentrievers are devices that have been designed by different companies to remove blood clots from arteries.

Up to a maximum of 500 people at 20-25 hospitals across Canada and other countries will participate in this study.


Options:
A: Arm Label: SOLITAIRE™ Device; Type: EXPERIMENTAL; Interventions: Device: SOLITAIRE™ Device | Arm Label: MERCI® Device; Type: ACTIVE_COMPARATOR; Interventions: Device: MERCI® Device | Intervention Type: DEVICE; Name: SOLITAIRE™ Device; Assigned to Arm(s): SOLITAIRE™ Device | Intervention Type: DEVICE; Name: MERCI® Device; Assigned to Arm(s): MERCI® Device
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: local interarterial recombinant tissue plasminogen activator | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous (IV) rt-PA | Intervention Type: DRUG; Name: local interarterial recombinant tissue plasminogen activator; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: intravenous (IV) rt-PA; Assigned to Arm(s): 2
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular thrombectomy/thrombolysis; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular thrombectomy/thrombolysis | Intervention Type: PROCEDURE; Name: Endovascular thrombectomy/thrombolysis; Assigned to Arm(s): Endovascular thrombectomy/thrombolysis
D: Arm Label: Intra-arterial Clot Retrieval after iv tPA; Type: EXPERIMENTAL; Interventions: Device: Intra-arterial Clot Retrieval with Solitaire device | Arm Label: Standard care iv tPA; Type: ACTIVE_COMPARATOR; Interventions: Genetic: intravenous tissue plasminogen activator (tPA) | Intervention Type: DEVICE; Name: Intra-arterial Clot Retrieval with Solitaire device; Assigned to Arm(s): Intra-arterial Clot Retrieval after iv tPA | Intervention Type: GENETIC; Name: intravenous tissue plasminogen activator (tPA); Assigned to Arm(s): Standard care iv tPA

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Advanced Comprehensive Diabetes Care for Veterans With Poorly-Controlled Diabetes
Brief Summary: This study will determine whether Home Telehealth-based implementation of an evidence-based intervention targeting Veterans with persistent poorly-controlled diabetes can improve hemoglobin A1c, patient self-management, and comorbid depressive symptoms in this high-risk, high-cost population. If effective, this intervention (Advanced Comprehensive Diabetes Care) offers a feasible, sustainable, and generalizable approach to managing Veterans with persistent poorly-controlled diabetes, which can be implemented using only existing Home Telehealth services.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Expanded Chronic Care Model | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Expanded Chronic Care Model; Assigned to Arm(s): 1
B: Intervention Type: BEHAVIORAL; Name: Nurse Case Manager and Community Health Worker Team; Assigned to Arm(s): N/A
C: Arm Label: Active Control Group (ACG); Type: OTHER; Interventions: Device: Accu-Chek Aviva Glucose Meter | Arm Label: Structured Testing Group (STG); Type: EXPERIMENTAL; Interventions: Device: Accu-Chek 360° View Blood Glucose Analysis Tool, Device: Accu-Chek Aviva Glucose Meter | Intervention Type: DEVICE; Name: Accu-Chek 360° View Blood Glucose Analysis Tool; Assigned to Arm(s): Structured Testing Group (STG) | Intervention Type: DEVICE; Name: Accu-Chek Aviva Glucose Meter; Assigned to Arm(s): Active Control Group (ACG), Structured Testing Group (STG)
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Home Telehealth with Behavioral Education Component | Intervention Type: BEHAVIORAL; Name: Home Telehealth with Behavioral Education Component; Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nasal Intermittent Mandatory Ventilation Versus Continuous Positive Airway Pressure After Extubation of Very Low Birth Weight Infants of the NEOCOSUR Network.
Brief Summary: The purpose of this study is to determine whether Nasal intermittent positive pressure ventilation (NIPPV) non synchronized is better than continuous positive airway pressure (NCPAP)in preventing extubation failure within 72 h, after extubation of very low birth weight infants at the NEOCOSUR Network.


Options:
A: Arm Label: NIMV- nasal respiratory support; Type: EXPERIMENTAL; Interventions: Device: NIMV with SLE ventilator vs HFNC via Vapotherm | Arm Label: HFNC- nasal respiratory support with HFNC; Type: EXPERIMENTAL; Interventions: Device: NIMV with SLE ventilator vs HFNC via Vapotherm | Intervention Type: DEVICE; Name: NIMV with SLE ventilator vs HFNC via Vapotherm; Assigned to Arm(s): HFNC- nasal respiratory support with HFNC, NIMV- nasal respiratory support
B: Arm Label: Nasal Continuous Positive Airway Pressure (CPAP); Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal CPAP (SLE) | Arm Label: Nasal Intermittent Mandatory Ventilation (IMV); Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal IMV (SLE) | Intervention Type: DEVICE; Name: Nasal CPAP (SLE); Assigned to Arm(s): Nasal Continuous Positive Airway Pressure (CPAP) | Intervention Type: DEVICE; Name: Nasal IMV (SLE); Assigned to Arm(s): Nasal Intermittent Mandatory Ventilation (IMV)
C: Arm Label: CPAP ventilation mode; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CPAP ventilation mode | Arm Label: NIPPV ventilation mode; Type: EXPERIMENTAL; Interventions: Procedure: NIPPV ventilation mode | Intervention Type: PROCEDURE; Name: CPAP ventilation mode; Assigned to Arm(s): CPAP ventilation mode | Intervention Type: PROCEDURE; Name: NIPPV ventilation mode; Assigned to Arm(s): NIPPV ventilation mode
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Device: nCPAP | Intervention Type: DEVICE; Name: nCPAP; Assigned to Arm(s): B | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nasal Intermittent Mandatory Ventilation Versus Continuous Positive Airway Pressure After Extubation of Very Low Birth Weight Infants of the NEOCOSUR Network.
Brief Summary: The purpose of this study is to determine whether Nasal intermittent positive pressure ventilation (NIPPV) non synchronized is better than continuous positive airway pressure (NCPAP)in preventing extubation failure within 72 h, after extubation of very low birth weight infants at the NEOCOSUR Network.


Options:
A: Arm Label: NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: nasal intermittent positive pressure ventilation | Arm Label: NIPPV; Type: EXPERIMENTAL; Interventions: Device: nasal intermittent positive pressure ventilation | Intervention Type: DEVICE; Name: nasal intermittent positive pressure ventilation; Assigned to Arm(s): NCPAP, NIPPV
B: Arm Label: NIPPV; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV
C: Arm Label: NAVA-PS; Type: EXPERIMENTAL; Interventions: Device: noninvasive respiratory support with NAVA mode and PSV | Arm Label: PS-NAVA; Type: EXPERIMENTAL; Interventions: Device: noninvasive respiratory support with NAVA mode and PSV | Intervention Type: DEVICE; Name: noninvasive respiratory support with NAVA mode and PSV; Assigned to Arm(s): NAVA-PS, PS-NAVA
D: Arm Label: CPAP ventilation mode; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CPAP ventilation mode | Arm Label: NIPPV ventilation mode; Type: EXPERIMENTAL; Interventions: Procedure: NIPPV ventilation mode | Intervention Type: PROCEDURE; Name: CPAP ventilation mode; Assigned to Arm(s): CPAP ventilation mode | Intervention Type: PROCEDURE; Name: NIPPV ventilation mode; Assigned to Arm(s): NIPPV ventilation mode

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor
Brief Summary: This is a study to determine how vaginal estrogen cream given for several weeks before pelvic reconstructive therapy will effect elastic fiber assembly in the muscularis layer of the vaginal wall. Postmenopausal women with at least Stage 2 pelvic organ prolapse will receive either estrogen vaginal cream or placebo cream 6-8 weeks prior to reconstructive surgery. At time of surgery, full thickness biopsies will be obtained from a standardized location at the top of vagina. The investigators will measure the thickness of the vaginal muscularis, elastic fiber number and morphology, and analyze if elastic fiber synthesis or degradation is affected by estrogen therapy. The results will provide important data to support a larger clinical trial to determine if preoperative and maintenance estrogen therapy alter long-term success rates of pelvic reconstructive surgery for pelvic organ prolapse.


Options:
A: Arm Label: Premarin; Type: EXPERIMENTAL; Interventions: Drug: Premarin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Premarin; Assigned to Arm(s): Premarin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: CO2 fractionated vaginal laser; Type: EXPERIMENTAL; Interventions: Device: CO2 fractionated vaginal laser | Arm Label: Estrogens, Conjugated (USP); Type: ACTIVE_COMPARATOR; Interventions: Drug: Estrogens, Conjugated (USP) | Intervention Type: DEVICE; Name: CO2 fractionated vaginal laser; Assigned to Arm(s): CO2 fractionated vaginal laser | Intervention Type: DRUG; Name: Estrogens, Conjugated (USP); Assigned to Arm(s): Estrogens, Conjugated (USP)
C: Arm Label: Study Group on estriol vaginal gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: estriol, Procedure: vaginal surgery | Arm Label: Control group, no estriol treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: vaginal surgery | Intervention Type: DRUG; Name: estriol; Assigned to Arm(s): Study Group on estriol vaginal gel | Intervention Type: PROCEDURE; Name: vaginal surgery; Assigned to Arm(s): Control group, no estriol treatment, Study Group on estriol vaginal gel
D: Arm Label: Premarin cream 0.5gm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vaginal conjugated estrogen cream 0.5gm | Arm Label: Premarin cream 1.0gm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vaginal conjugated estrogen cream 1.0gm | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Vaginal conjugated estrogen cream 0.5gm; Assigned to Arm(s): Premarin cream 0.5gm | Intervention Type: DRUG; Name: Vaginal conjugated estrogen cream 1.0gm; Assigned to Arm(s): Premarin cream 1.0gm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II/III Trial Investigating if Concomitant Injections of the Diagnostic Agents C-Tb and 2 T.U Tuberculin PPD RT 23 SSI Affect the Induration Responses in Combination With a Safety Assessment of C-Tb
Brief Summary: A new, more specific skin test to detect tuberculosis has been developed by Statens Serum Institut in Denmark. The new skin test is named C-Tb and like the current Tuberculin a positive test result will show as redness and/or induration at the injection site, while a negative test will leave no reactions.

The aim of this study is to address if the size of induration and the sensitivity of C-Tb is influenced by concomitant injections of C-Tb and Tuberculin. Furthermore, the intention is to evaluate the safety of C-Tb when injected alone or concomitantly with Tuberculin.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Interventional; Type: EXPERIMENTAL; Interventions: Diagnostic Test: Xpert MTB/RIF Ultra (Ultra) | Intervention Type: DIAGNOSTIC_TEST; Name: Xpert MTB/RIF Ultra (Ultra); Assigned to Arm(s): Interventional
B: Arm Label: Facility-based screening; Type: EXPERIMENTAL; Interventions: Other: Active TB case finding | Arm Label: Contact screening; Type: EXPERIMENTAL; Interventions: Other: Active TB case finding | Intervention Type: OTHER; Name: Active TB case finding; Assigned to Arm(s): Contact screening, Facility-based screening
C: Arm Label: 0.1 µg C-Tb; Type: EXPERIMENTAL; Interventions: Biological: C-Tb | Arm Label: 2 T.U Tuberculin PPD RT 23 SSI; Type: ACTIVE_COMPARATOR; Interventions: Biological: Tuberculin PPD RT 23 SSI | Arm Label: 0.1 µg C-Tb / 2 T.U Tuberculin PPD; Type: EXPERIMENTAL; Interventions: Biological: C-Tb / Tuberculin PPD RT 23 SSI | Intervention Type: BIOLOGICAL; Name: C-Tb; Assigned to Arm(s): 0.1 µg C-Tb | Intervention Type: BIOLOGICAL; Name: Tuberculin PPD RT 23 SSI; Assigned to Arm(s): 2 T.U Tuberculin PPD RT 23 SSI | Intervention Type: BIOLOGICAL; Name: C-Tb / Tuberculin PPD RT 23 SSI; Assigned to Arm(s): 0.1 µg C-Tb / 2 T.U Tuberculin PPD
D: Arm Label: 0.1 µg/0.1 mL C-Tb; Type: EXPERIMENTAL; Interventions: Biological: C-Tb | Arm Label: 2 T.U. Tuberculin PPD RT 23 SSI; Type: ACTIVE_COMPARATOR; Interventions: Biological: 2 T.U. Tuberculin PPD RT 23 SSI | Intervention Type: BIOLOGICAL; Name: C-Tb; Assigned to Arm(s): 0.1 µg/0.1 mL C-Tb | Intervention Type: BIOLOGICAL; Name: 2 T.U. Tuberculin PPD RT 23 SSI; Assigned to Arm(s): 2 T.U. Tuberculin PPD RT 23 SSI

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
Brief Summary: Trial for the optimization of risk assessment and therapy success prediction in patients with early breast cancer by the use of biomarkers in advance to therapy decision-making to personalize therapies.


Options:
A: Arm Label: Anthracycline - Taxane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epirubicin, Drug: Cyclophosphamide, Drug: Docetaxel, Drug: Paclitaxel | Arm Label: Taxane - Anthracycline; Type: EXPERIMENTAL; Interventions: Drug: Epirubicin, Drug: Cyclophosphamide, Drug: Docetaxel, Drug: Paclitaxel | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): Anthracycline - Taxane, Taxane - Anthracycline | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Anthracycline - Taxane, Taxane - Anthracycline | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Anthracycline - Taxane, Taxane - Anthracycline | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Anthracycline - Taxane, Taxane - Anthracycline
B: Arm Label: Doxorubicin-Cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Doxorubicin | Arm Label: Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Cisplatin | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Doxorubicin-Cyclophosphamide | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Doxorubicin-Cyclophosphamide
C: Arm Label: Paclitaxel with Carboplatin (PwCb); Type: ACTIVE_COMPARATOR; Interventions: Drug: PwCb, Drug: EC, Procedure: Surgery after neoadjuvant Therapy, Other: Stratification | Arm Label: Paclitaxel with Olaparib (PwO); Type: EXPERIMENTAL; Interventions: Drug: PwO, Drug: EC, Procedure: Surgery after neoadjuvant Therapy, Other: Stratification | Intervention Type: DRUG; Name: PwO; Assigned to Arm(s): Paclitaxel with Olaparib (PwO) | Intervention Type: DRUG; Name: PwCb; Assigned to Arm(s): Paclitaxel with Carboplatin (PwCb) | Intervention Type: DRUG; Name: EC; Assigned to Arm(s): Paclitaxel with Carboplatin (PwCb), Paclitaxel with Olaparib (PwO) | Intervention Type: PROCEDURE; Name: Surgery after neoadjuvant Therapy; Assigned to Arm(s): Paclitaxel with Carboplatin (PwCb), Paclitaxel with Olaparib (PwO) | Intervention Type: OTHER; Name: Stratification; Assigned to Arm(s): Paclitaxel with Carboplatin (PwCb), Paclitaxel with Olaparib (PwO)
D: Arm Label: Induction Therapy; Type: EXPERIMENTAL; Interventions: Other: Induction therapy | Intervention Type: OTHER; Name: Induction therapy; Assigned to Arm(s): Induction Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Restoring Insulin Secretion Adult Medication Study
Brief Summary: The RISE Adult Medication Study is a 4-arm, 3-center, clinical trial of adults with prediabetes and early type 2 diabetes to address the hypothesis that aggressive glucose lowering will lead to recovery of beta-cell function that will be sustained after withdrawal of treatment. Adult participants (ages 20-65) will be randomized to one of the following treatment regimens: (1) blinded placebo, (2) blinded metformin alone, (3) early intensive insulin treatment with basal insulin glargine followed by open-label metformin, (4) the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide plus open-label metformin.

The primary clinical question RISE will address is: Are improvements in ß-cell function following 12 months of active treatment maintained for 3 months following the withdrawal of therapy? Secondary outcomes will assess durability of glucose tolerance following withdrawal of therapy, and whether biomarkers obtained in the fasting state predict parameters of ß-cell function, insulin sensitivity and glucose tolerance and the response to an intervention.


Options:
A: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: gastric banding; Type: EXPERIMENTAL; Interventions: Device: gastric banding | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): metformin | Intervention Type: DEVICE; Name: gastric banding; Assigned to Arm(s): gastric banding
B: Arm Label: Liraglutide 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
D: Arm Label: Metformin alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Glargine followed by Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Glargine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Liraglutide + Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Liraglutide | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glargine followed by Metformin, Liraglutide + Metformin, Metformin alone | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide + Metformin | Intervention Type: DRUG; Name: Glargine; Assigned to Arm(s): Glargine followed by Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Restoring Insulin Secretion Pediatric Medication Study
Brief Summary: The RISE Pediatric Medication Study is a 2-arm, 4-center, clinical trial of children with prediabetes and early type 2 diabetes to address the hypothesis that aggressive glucose lowering will lead to recovery of beta-cell function that will be sustained after withdrawal of treatment. Pediatric participants (ages 10-19) will be randomized to one of the following treatment regimens: (1) metformin alone or (2) early intensive treatment with basal insulin glargine followed by metformin.

The primary clinical question RISE will address is: Are improvements in ß-cell function following 12 months of active treatment maintained for 3 months following the withdrawal of therapy? Secondary outcomes will assess durability of glucose tolerance following withdrawal of therapy, and whether biomarkers obtained in the fasting state predict parameters of ß-cell function, insulin sensitivity and glucose tolerance and the response to an intervention.


Options:
A: Arm Label: Metformin alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Glargine followed by Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Glargine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Liraglutide + Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Liraglutide | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glargine followed by Metformin, Liraglutide + Metformin, Metformin alone | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide + Metformin | Intervention Type: DRUG; Name: Glargine; Assigned to Arm(s): Glargine followed by Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Normal Saline | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide | Intervention Type: OTHER; Name: Normal Saline; Assigned to Arm(s): Placebo
C: Arm Label: Liraglutide 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Metformin alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Glargine followed by Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Glargine | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glargine followed by Metformin, Metformin alone | Intervention Type: DRUG; Name: Glargine; Assigned to Arm(s): Glargine followed by Metformin

Answer: D